QWINT-1 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin glargine for 52 weeks in insulin naïve patients. The trial met its primary endpoint of non ...

At present no reports on glulisine use in pregnancy are available. [53] Insulin Glargine. The first long-acting insulin analogue was approved for clinical use in patients with Type 1 and Type 2 ...

Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.

It contains the active drug insulin glargine, a long-acting form of insulin. Also called basal or background insulin, these insulin types do not peak like shorter-acting insulins and can help ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...

The development follows an announcement in December 2024 when EVA Pharma and Eli Lilly received approval from the Egyptian ...